Related Experiment Videos
Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding
M M Eibl1, H M Wolf, H Fürnkranz
1Institute of Immunology, University of Vienna, Austria.
Insights
Oral immunoglobulin (IgA-IgG) supplementation significantly reduced necrotizing enterocolitis in low-birth-weight infants lacking maternal breast milk. This oral treatment offers a promising preventative strategy for vulnerable newborns.
Area of Science:
- Neonatology
- Immunology
- Gastroenterology
Background:
- Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease affecting premature and low-birth-weight infants.
- Limited access to maternal breast milk increases NEC risk in vulnerable infant populations.
- Oral immunoglobulins are being explored as a potential preventative measure against NEC.
Purpose of the Study:
- To evaluate the efficacy of oral immunoglobulin preparation (IgA-IgG) in preventing NEC.
- To assess the impact of oral IgA-IgG in low-birth-weight infants without available maternal breast milk.
Main Methods:
- A randomized clinical trial involving 434 low-birth-weight infants (800-2000 g).
- Infants received either oral IgA-IgG or a control treatment for 28 days.
- Follow-up assessed NEC incidence, with subgroup analysis for infants who did not receive breast milk.
Main Results:
- No NEC cases occurred in the 88 infants receiving oral IgA-IgG (vs. 6 in 91 controls, P=0.0143) among those without breast milk.
- Two cases of NEC were reported among withdrawn control infants.
- Oral IgA-IgG administration showed a statistically significant reduction in NEC incidence.
Conclusions:
- Oral IgA-IgG administration may be an effective strategy to prevent necrotizing enterocolitis in high-risk low-birth-weight infants.
- This intervention is particularly relevant for infants who cannot access maternal breast milk.
- Further research may support the routine use of oral immunoglobulins in neonatal intensive care units.
Abstract:
In a randomized clinical trial, we evaluated the efficacy of an oral immunoglobulin preparation (73 percent IgA and 26 percent IgG) in reducing the incidence of necrotizing enterocolitis in infants of low birth weight for whom breast milk from their mothers was not available. A total of 434 infants weighing between 800 and 2000 g were eligible for entry in the study. Of these, 255 were withdrawn - 234 during the first week of the study because breast milk from their mothers became available (123 in the treatment group and 111 in the control group), and 21 because of violations of protocol or because breast milk became available after the first week. The duration of follow-up was 28 days. Among the infants for whom breast milk did not become available during the study, there were no cases of necrotizing enterocolitis among the 88 receiving oral IgA-IgG, as compared with six cases among the 91 control infants (P = 0.0143). Of the infants withdrawn from the study, two assigned to the control group had necrotizing enterocolitis. We conclude that the oral administration of IgA-IgG may prevent the development of necrotizing enterocolitis in low-birth-weight infants.